Skip to main content
Erschienen in: Im Fokus Onkologie 5/2022

24.10.2022 | Urothelkarzinom | Uroonkologie

Nicht muskelinvasives Urothelkarzinom der Harnblase

Neue Substanzen könnten bald die Behandlungsmöglichkeiten erweitern

verfasst von: Prof. Dr. med. Georgios Gakis

Erschienen in: Im Fokus Onkologie | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Auszug

Beim nicht muskelinvasiven Harnblasenkarzinom ist die Instillation nach wie vor die Standardtherapie. Die Chancen stehen gut, dass das pharmakologische Instrumentarium neben den derzeitigen Behandlungsmöglichkeiten gemäß den aktuellen Leitlinien bald um neue Substanzen erweitert wird. …
Literatur
1.
Zurück zum Zitat Gudjonsson S et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol. 2009; 55(4):773-80 Gudjonsson S et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol. 2009; 55(4):773-80
2.
Zurück zum Zitat De Nunzio C et al. Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial. World J Urol. 2011;29(4):517-21 De Nunzio C et al. Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial. World J Urol. 2011;29(4):517-21
4.
Zurück zum Zitat Bohle A et al. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol. 2009; 56(3):495-503 Bohle A et al. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol. 2009; 56(3):495-503
5.
Zurück zum Zitat Jones G et al. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2012; 1:CD009294 Jones G et al. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2012; 1:CD009294
6.
Zurück zum Zitat Shelley MD et al. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. BJU Int. 2012;109(4):496-505 Shelley MD et al. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. BJU Int. 2012;109(4):496-505
7.
Zurück zum Zitat Li R et al. Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial. BMC Urol. 2020; 20(1):97 Li R et al. Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial. BMC Urol. 2020; 20(1):97
8.
Zurück zum Zitat Sylvester RJ et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010; 57(5):766-73 Sylvester RJ et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010; 57(5):766-73
9.
Zurück zum Zitat Di Lorenzo G et al. Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer. 2010; 116(8):1893-900 Di Lorenzo G et al. Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer. 2010; 116(8):1893-900
10.
Zurück zum Zitat Addeo R et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol. 2010; 28(4):543-8 Addeo R et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol. 2010; 28(4):543-8
11.
Zurück zum Zitat Grimberg DC et al. Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer. Eur Urol Focus. 2020; 6(4):620-2 Grimberg DC et al. Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer. Eur Urol Focus. 2020; 6(4):620-2
12.
Zurück zum Zitat Di Stasi SM et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res. 1999; 59(19):4912-8 Di Stasi SM et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res. 1999; 59(19):4912-8
13.
Zurück zum Zitat Di Stasi SM et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006; 7(1):43-51 Di Stasi SM et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006; 7(1):43-51
15.
Zurück zum Zitat Shore ND et al. Intravesical rAd-IFNalpha/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017; 35(30):3410-6 Shore ND et al. Intravesical rAd-IFNalpha/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017; 35(30):3410-6
16.
Zurück zum Zitat Boorjian SA et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021; 22(1):107-17 Boorjian SA et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021; 22(1):107-17
17.
Zurück zum Zitat Kramer MW, Gakis G. Immuno-oncological therapeutic options in high-risk non-muscle invasive bladder cancer. Urologe A. 2020; 59(7):784-9 Kramer MW, Gakis G. Immuno-oncological therapeutic options in high-risk non-muscle invasive bladder cancer. Urologe A. 2020; 59(7):784-9
18.
Zurück zum Zitat Kowalski M et al. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin. J Urol. 2012; 188(5):1712-8 Kowalski M et al. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin. J Urol. 2012; 188(5):1712-8
19.
Zurück zum Zitat Rosser CJ et al. Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guerin (BCG) for the Treatment of Bladder Cancer. Oncoimmunology. 2021; 10(1):1912885 Rosser CJ et al. Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guerin (BCG) for the Treatment of Bladder Cancer. Oncoimmunology. 2021; 10(1):1912885
20.
Zurück zum Zitat Mostafid AH et al. CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. BJU Int. 2020;125(6):817-26 Mostafid AH et al. CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. BJU Int. 2020;125(6):817-26
Metadaten
Titel
Nicht muskelinvasives Urothelkarzinom der Harnblase
Neue Substanzen könnten bald die Behandlungsmöglichkeiten erweitern
verfasst von
Prof. Dr. med. Georgios Gakis
Publikationsdatum
24.10.2022
Verlag
Springer Medizin
Erschienen in
Im Fokus Onkologie / Ausgabe 5/2022
Print ISSN: 1435-7402
Elektronische ISSN: 2192-5674
DOI
https://doi.org/10.1007/s15015-022-2902-7

Weitere Artikel der Ausgabe 5/2022

Im Fokus Onkologie 5/2022 Zur Ausgabe

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.